Join
Live feed
·
PRReleasevia Quantisnow
Biomea Fusion Inc. logo

Biomea Fusion Presents Preclinical Data Showing Icovamenib (BMF-219) Enhanced Effectiveness of GLP-1-Based Therapies and Introduces BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist Candidate

ByQuantisnow·Wall Street's wire, on your screen.
BMEA· Biomea Fusion Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track BMEA (Biomea Fusion Inc.) and more on Quantisnow.